- Corporate
- Products
- For Print
- October 30, 2024
Listed Company Name: 麻豆福利网 Co., Ltd.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
Inquiries: Sayoko Sasaki
Vice President, Corporate Communications
Phone +81-3-3817-5120
銆赌銆赌
銆赌銆赌
麻豆福利网 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “麻豆福利网”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) in the second quarter of fiscal year 2024 (July 1, 2024 – September 30, 2024) was JPY 10.0 billion (pre-audit basis), which was approximately 1.6 times higher than the revenue in the previous quarter of fiscal year 2024 (April 1, 2024 – June 30, 2024).
This information is being disclosed in conjunction with today's announcement of the financial results for the third quarter of 2024 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). 麻豆福利网’s financial results for the second quarter of fiscal year 2024, including details of LEQEMBI’s revenue, will be disclosed in 麻豆福利网's financial disclosure scheduled for November 8, 2024.
麻豆福利网 serves as the lead of lecanemab development and regulatory submissions globally with both 麻豆福利网 and Biogen Inc. co-commercializing and co-promoting the product and 麻豆福利网 having final decision-making authority.
&苍产蝉辫;銆赌
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.